This study is testing a new treatment called NKX019 for autoimmune diseases like Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, and Rheumatoid Arthritis. NKX019 is a type of cell therapy that targets specific cells in your body. Before receiving NKX019, you would get other medications called fludarabine and cyclophosphamide to prepare your body. The main goals of this study are to see how safe NKX019 is and what side effects it might cause. We are also looking at how well it works. You might be able to join if you are between 18 and 75 years old. The study aims to enroll 240 participants, but its current status is unclear.

Study design

This is a Phase 1/2, open-label study, meaning both you and your doctors will know which treatment you are receiving. It will involve a dose escalation phase to find the right dose, followed by an expansion phase with more participants.

What's involved

You would receive a cycle of lymphodepletion medications (fludarabine and cyclophosphamide) followed by three doses of NKX019. You would need to follow a specific study visit schedule and other protocol requirements.

Compensation

Not stated in the trial record.

Follow-up

Safety will be measured for the first 28 days after the first NKX019 dose, and for 30 days after the last study treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.